Andrew J Toner1, Vyhunthan Ganeshanathan, Matthew T Chan, Kwok M Ho, Tomas B Corcoran. 1. From the Department of Anaesthesia and Pain Medicine, Royal Perth Hospital, Perth, Western Australia, Australia (A.J.T., V.G., T.B.C.); Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Hong Kong (M.T.C.); Department of Intensive Care Medicine, Royal Perth Hospital, Perth, Western Australia, Australia (K.M.H.); School of Population Health, University of Western Australia, Perth, Western Australia, Australia (K.M.H.); School of Veterinary and Life Sciences, Murdoch University, Perth, Western Australia, Australia (K.M.H.); School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia (T.B.C.); and School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia (T.B.C.).
Abstract
BACKGROUND: Glucocorticoids are increasingly used perioperatively, principally to prevent nausea and vomiting. Safety concerns focus on the potential for hyperglycemia and increased infection. The authors hypothesized that glucocorticoids predispose to such adverse outcomes in a dose-dependent fashion after elective noncardiac surgery. METHODS: The authors conducted a systematic literature search of the major medical databases from their inception to April 2016. Randomized glucocorticoid trials in adults specifically reporting on a safety outcome were included and meta-analyzed with Peto odds ratio method or the quality effects model. Subanalyses were performed according to a dexamethasone dose equivalent of low (less than 8 mg), medium (8 to 16 mg), and high (more than 16 mg). The primary endpoints of any wound infection and peak perioperative glucose concentrations were subject to meta-regression. RESULTS: Fifty-six trials from 18 countries were identified, predominantly assessing dexamethasone. Glucocorticoids did not impact on any wound infection (odds ratio, 0.8; 95% CI, 0.6 to 1.2) but did result in a clinically unimportant increase in peak perioperative glucose concentration (weighted mean difference, 20.0 mg/dl; CI, 11.4 to 28.6; P < 0.001 or 1.1 mM; CI, 0.6 to 1.6). Glucocorticoids reduced peak postoperative C-reactive protein concentrations (weighted mean difference, -22.1 mg/l; CI, -31.7 to -12.5; P < 0.001), but other adverse outcomes and length of stay were unchanged. No dose-effect relationships were apparent. CONCLUSIONS: The evidence at present does not highlight any safety concerns with respect to the use of perioperative glucocorticoids and subsequent infection, hyperglycemia, or other adverse outcomes. Nevertheless, collated trials lacked sufficient surveillance and power to detect clinically important differences in complications such as wound infection.
BACKGROUND: Glucocorticoids are increasingly used perioperatively, principally to prevent nausea and vomiting. Safety concerns focus on the potential for hyperglycemia and increased infection. The authors hypothesized that glucocorticoids predispose to such adverse outcomes in a dose-dependent fashion after elective noncardiac surgery. METHODS: The authors conducted a systematic literature search of the major medical databases from their inception to April 2016. Randomized glucocorticoid trials in adults specifically reporting on a safety outcome were included and meta-analyzed with Peto odds ratio method or the quality effects model. Subanalyses were performed according to a dexamethasone dose equivalent of low (less than 8 mg), medium (8 to 16 mg), and high (more than 16 mg). The primary endpoints of any wound infection and peak perioperative glucose concentrations were subject to meta-regression. RESULTS: Fifty-six trials from 18 countries were identified, predominantly assessing dexamethasone. Glucocorticoids did not impact on any wound infection (odds ratio, 0.8; 95% CI, 0.6 to 1.2) but did result in a clinically unimportant increase in peak perioperative glucose concentration (weighted mean difference, 20.0 mg/dl; CI, 11.4 to 28.6; P < 0.001 or 1.1 mM; CI, 0.6 to 1.6). Glucocorticoids reduced peak postoperative C-reactive protein concentrations (weighted mean difference, -22.1 mg/l; CI, -31.7 to -12.5; P < 0.001), but other adverse outcomes and length of stay were unchanged. No dose-effect relationships were apparent. CONCLUSIONS: The evidence at present does not highlight any safety concerns with respect to the use of perioperative glucocorticoids and subsequent infection, hyperglycemia, or other adverse outcomes. Nevertheless, collated trials lacked sufficient surveillance and power to detect clinically important differences in complications such as wound infection.
Authors: Nicolai A Schultz; Peter N Larsen; B Klarskov; L M Plum; Hans-Jørgen Frederiksen; Henrik Kehlet; Jens G Hillingsø Journal: World J Surg Date: 2018-06 Impact factor: 3.352
Authors: Jorinde Aw Polderman; Violet Farhang-Razi; Susan Van Dieren; Peter Kranke; J Hans DeVries; Markus W Hollmann; Benedikt Preckel; Jeroen Hermanides Journal: Cochrane Database Syst Rev Date: 2018-08-28
Authors: Karim Asehnoune; Charlene Le Moal; Gilles Lebuffe; Marguerite Le Penndu; Nolwen Chatel Josse; Matthieu Boisson; Thomas Lescot; Marion Faucher; Samir Jaber; Thomas Godet; Marc Leone; Cyrus Motamed; Jean Stephane David; Raphael Cinotti; Younes El Amine; Darius Liutkus; Matthias Garot; Antoine Marc; Anne Le Corre; Alexandre Thomasseau; Alexandra Jobert; Laurent Flet; Fanny Feuillet; Morgane Pere; Emmanuel Futier; Antoine Roquilly Journal: BMJ Date: 2021-06-02
Authors: Jorinde Aw Polderman; Violet Farhang-Razi; Susan Van Dieren; Peter Kranke; J Hans DeVries; Markus W Hollmann; Benedikt Preckel; Jeroen Hermanides Journal: Cochrane Database Syst Rev Date: 2018-11-23